Klacid

Clarithromycin, the active ingredient in Klacid, is a macrolide presented as an injectable solution for intravenous use. It treats a range of bacterial infections, including community‑acquired pneumonia, acute bacterial sinusitis, chronic bronchitis exacerbations, skin and soft‑tissue infections, and is used in combination regimens for Helicobacter pylori eradication.

GNH USA supplies Klacid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Klacid (clarithromycin) is a macrolide antibiotic used to treat bacterial infections of the respiratory and skin systems.

- Community‑acquired pneumonia: effective in eradicating susceptible Streptococcus pneumoniae and other typical pathogens. - Acute bacterial sinusitis: reduces bacterial load and alleviates sinus inflammation. - Acute exacerbations of chronic bronchitis: shortens symptom duration and improves lung function. - Skin and soft‑tissue infections: targets Staphylococcus aureus and Streptococcus species. - Helicobacter pylori eradication (in combination therapy): contributes to bacterial clearance when used with a proton‑pump inhibitor and another antimicrobial.

Clarithromycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools that may be watery. - Abdominal pain or discomfort. - Altered taste sensation (metallic or bitter). - Headache: transient and usually resolves. - Vomiting: occasional episodes during therapy.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or jaundice. - QT interval prolongation: risk of cardiac arrhythmias. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Clostridioides difficile infection: may lead to pseudomembranous colitis. - Hepatic failure: rare but life‑threatening. - Stevens‑Johnson syndrome: severe skin reaction.

Before initiating clarithromycin therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Assess renal and hepatic function: adjust therapy if impairment is present. - Monitor cardiac status: avoid use in patients with known QT prolongation. - Review concomitant QT‑prolonging drugs: avoid additive risk. - Evaluate drug interaction profile: check patient medication list for macrolide interactions. - Pregnancy and lactation: use only if benefit outweighs risk (Category B). - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Clarithromycin interacts with several drug classes; awareness of the interaction severity guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may cause toxic plasma levels. - Concurrent QT‑prolonging agents (e.g., quinolones, antiarrhythmics): increase risk of arrhythmia. - Colchicine in renal impairment: can lead to severe toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce clarithromycin efficacy. - Warfarin: clarithromycin can increase INR; monitor coagulation parameters. - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): may raise statin levels; watch for myopathy.